CAMBRIDGE, Mass.– Mispro, a leading provider of contract vivarium research space and services, has appointed Yohan Tessier as president and chief operating officer, effective Jan. 1, 2025.
Since joining Mispro in 2007, Tessier has been instrumental in transforming the company’s contract vivarium model into a critical component of the life sciences ecosystem. His strategic vision has driven Mispro’s expansion into leading biotech markets, positioning its facilities as essential amenities within life science campuses and making contract vivarium access an integral part of preclinical research infrastructure.
“Yohan has been a driving force behind Mispro’s evolution and success, and his strategic vision has defined our company as a leader in the contract vivarium space,” said Philippe Lamarre, CEO of Mispro. “His promotion to president and COO reflects our confidence in his ability to lead Mispro into its next phase of growth.”
Tessier has played a pivotal role in expanding Mispro’s footprint by strategically positioning facilities within key life science clusters, ensuring seamless access for biotech and pharmaceutical companies. In addition to leading location strategy and operational efficiencies, he has reimagined vivarium environments by incorporating collaboration spaces, natural light, and color—elements that challenge traditional perceptions of preclinical research facilities. By streamlining operations and transitioning to an all-inclusive space plus services model, he has strengthened Mispro’s role as an indispensable resource for preclinical drug development, further integrating the contract vivarium model into the broader innovation ecosystem.
In his expanded role, Tessier will spearhead high-impact growth initiatives, including forging strategic partnerships with venture capital firms, incubators, and life science real estate leaders to integrate contract vivarium facilities directly into the innovation pipeline of emerging biotech companies. As Mispro expands in metro Boston/Cambridge, the Bay Area, and into San Diego in 2026, his leadership will be key to shaping the company’s continued influence in preclinical research.
